# NLA101 in Adults Receiving High Dose Chemotherapy for AML

> **NCT03301597** · PHASE2 · TERMINATED · sponsor: **Nohla Therapeutics, Inc.** · enrollment: 146 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **BIOLOGICAL:** NLA101
- **DRUG:** Standard of Care (SOC) chemotherapy

## Key facts

- **NCT ID:** NCT03301597
- **Lead sponsor:** Nohla Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-01-24
- **Primary completion:** 2019-03-18
- **Final completion:** 2019-03-18
- **Target enrollment:** 146 (ACTUAL)
- **Why stopped:** Development plan under review.
- **Last updated:** 2021-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301597, "NLA101 in Adults Receiving High Dose Chemotherapy for AML". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03301597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*